Skip to search formSkip to main contentSkip to account menu

TG4010

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A… 
Review
2014
Review
2014
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy… 
2012
2012
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as… 
2012
2012
TPS7610 Background: TG4010 is an immunotherapy product based on a poxvirus (MVA) coding for the MUC1 tumor-associated antigen and… 
2011
2011
Chemotherapy is the standard of care for patients with advanced-stage non-small-cell lung cancer (NSCLC), and it is widely agreed… 
2009
2009
3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a… 
2008
2008
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1… 
2007
2007
Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at… 
2006
2006
2581 Background: MUC1 is a glycoprotein often over-expressed and underglycosylated in renal cell carcinoma (RCC) making it an…